373 related articles for article (PubMed ID: 24122306)
21. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
[TBL] [Abstract][Full Text] [Related]
22. Riociguat for pulmonary hypertension.
Cannon JE; Pepke-Zaba J
Expert Rev Clin Pharmacol; 2014 May; 7(3):259-70. PubMed ID: 24580082
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary arterial hypertension: a review in pharmacotherapy.
Patel BB; Feng Y; Cheng-Lai A
Cardiol Rev; 2015; 23(1):33-51. PubMed ID: 25275717
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary hypertension: role of combination therapy.
Meis T; Behr J
Curr Vasc Pharmacol; 2011 Jul; 9(4):457-64. PubMed ID: 21143162
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic therapy for pulmonary artery hypertension.
Nair A
Curr Opin Cardiol; 2020 Nov; 35(6):643-656. PubMed ID: 32897888
[TBL] [Abstract][Full Text] [Related]
26. New horizons in pulmonary arterial hypertension therapies.
Galiè N; Ghofrani AH
Eur Respir Rev; 2013 Dec; 22(130):503-14. PubMed ID: 24293466
[TBL] [Abstract][Full Text] [Related]
27. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapies in pulmonary arterial hypertension.
Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
[TBL] [Abstract][Full Text] [Related]
29. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview.
Raja SG
Cardiovasc Ther; 2010 Oct; 28(5):e65-71. PubMed ID: 20406243
[TBL] [Abstract][Full Text] [Related]
30. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
Small M; Piercy J; Pike J; Cerulli A
Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
[TBL] [Abstract][Full Text] [Related]
31. New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension.
Hill NS; Cawley MJ; Heggen-Peay CL
J Manag Care Spec Pharm; 2016 Mar; 22(3 Suppl A):S3-21. PubMed ID: 27003666
[TBL] [Abstract][Full Text] [Related]
32. New and future therapies in pulmonary arterial hypertension.
Bull TM
Semin Respir Crit Care Med; 2005 Aug; 26(4):429-36. PubMed ID: 16121320
[TBL] [Abstract][Full Text] [Related]
33. Selexipag for the treatment of pulmonary arterial hypertension.
Noel ZR; Kido K; Macaulay TE
Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
[TBL] [Abstract][Full Text] [Related]
34. Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.
Oishi P; Datar SA; Fineman JR
Expert Opin Pharmacother; 2011 Aug; 12(12):1845-64. PubMed ID: 21609302
[TBL] [Abstract][Full Text] [Related]
35. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
Wang S; Yu M; Zheng X; Dong S
Drug Deliv; 2018 Nov; 25(1):1898-1909. PubMed ID: 30442035
[TBL] [Abstract][Full Text] [Related]
36. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
Osvaldo Cáneva J; Ossés JM
Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
[TBL] [Abstract][Full Text] [Related]
37. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
Price LC; Howard LS
Am J Cardiovasc Drugs; 2008; 8(3):171-85. PubMed ID: 18533738
[TBL] [Abstract][Full Text] [Related]
38. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
39. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension.
Monaco TJ; Davila CD
Drug Des Devel Ther; 2016; 10():1675-82. PubMed ID: 27274200
[TBL] [Abstract][Full Text] [Related]
40. Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension.
Gildea TR; Arroliga AC; Minai OA
Cleve Clin J Med; 2003 Apr; 70 Suppl 1():S18-27. PubMed ID: 12716139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
